Effectiveness and Safety of Topical Finasteride for Male Androgenetic Alopecia: Real World Data

This review article examines current drugs for androgenetic alopecia, focusing on their mechanisms and clinical efficacy, noting that while finasteride and minoxidil are commonly approved treatments, new drugs targeting different pathogenic pathways have emerged, offering a broader understanding and reference for AGA treatment options.

In this study, analysis of FDA adverse event reports revealed that topical finasteride was associated with fewer post-finasteride syndrome-like adverse events than oral finasteride, but many reports lack critical data, suggesting caution in attributing causality.

Dutasteride and finasteride do not increase mood disorder risk in men with hair loss.

In this report, a rare case of gynecomastia was observed in a 76-year-old man using 0.25% topical finasteride for hair loss, with breast tenderness resolving after stopping treatment but persistent enlargement.

This study found that topical finasteride mixed with minoxidil improved hair appearance and self-esteem in men with androgenetic alopecia, but it was not superior to oral finasteride and had lower treatment adherence.

This review found that topical finasteride has similar efficacy to oral finasteride in treating male and female pattern hair loss, with fewer systemic side effects, mainly causing localized scalp reactions like irritation and erythema.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This study developed a standardized questionnaire to measure patient-perceived changes in hair growth and appearance, which showed significant favoring of active treatment over placebo in a clinical trial for male androgenetic alopecia.